Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light or nerve zap: which eases diabetic nerve pain better?

NCT ID NCT07078058

Symptom relief Sponsor: Horus University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two non-invasive treatments—low-level laser and transcutaneous vagus nerve stimulation—in 30 adults with diabetic neuropathy. The goal was to see which better improves blood flow and reduces nerve pain. Participants had diabetes for over 5 years and stable blood sugar control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Aug 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The patient selection will be according to the following criteria: 1. 30 patients diagnosed with diabetic neuropathy from both genders their ages will be ranged from 45-60 years old. 2. All patients are ambulant independently. 3. All patients are under full medical control 4. Glycated hemoglobin is ranged from 6.5: 7 %. 5. Patients have had diabetes for more than 5 or 10 years. 6. patients experiencing painful peripheral neuropathic symptoms for more than 6 months involving both lower extremities and complained of burning pain with paresthesia in both legs. 7 Neurological examination revealed abnormal sensation appeared at the ends of the extremities. Exclusion Criteria: 1. Patients had unstable glycemic control and/or medical conditions that would confound assessment of neuropathy such as malignancy, active/untreated thyroid disease, peripheral vascular diseases, vascular insufficiency (claudication, skin discoloration, ulceration). 2. Following the implantation of cardiac pacemakers or other electrical stimulation devices. 3. Patient had sinus bradycardia, long QT syndrome, or other arrhythmias or mental disorders. 4. Patients whose heart rate dropped below 50 beats/min after vagus nerve stimulation. 5. Nerve damage as a result of prior reconstructive or replacement knee surgery, back surgery, spinal stenosis, spinal compression or radiculopathy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic peripheral neuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic neuropathy diabetic polyneuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic peripheral neuropathy Transcutaneous vagus nerve stimulation

Contacts and locations

Locations

  • out-patient clinic, faculty of physical therapy, Horus university

    Damietta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.